Neurochemical Journal

, Volume 1, Issue 3, pp 260–263 | Cite as

Estimation of the antioxidant effect of the nootropic dipeptide Noopept on the model of Fe2+-induced chemiluminescence of lipoproteins of human serum in vitro

Experimental Articles
  • 56 Downloads

Abstract

The antioxidative activity of the nootropic dipeptide Noopept (the ethyl ether of N-phenylacetyl-L-prolyglycine, GVS-111) was studied on a model of Fe2+-induced chemiluminescence (CL) of serum lipoproteins from healthy human donors in vitro. Efficiency of the following antioxidant agents has been compared: Noopept, pyracetam (the non-peptide prototype of Noopept), the PBN antioxidant (N-tert-butyl-α-phenylnitron that acts as a free radical trap), and mannitol, which is used as a neuroprotective drug in the treatment of brain edema. Noopept was shown to modulate the duration of the CL latent period (gt) that reflected an endogenous antioxidant potential. Noopept and PBN caused a maximum increase in this parameter of 3.4 and 3 times relative to the control, respectively. At the same time, Noopept appeared to be more effective, because it acted at lower concentrations compared to PBN. Our results demonstrated that Noopept protected human serum lipoproteins from Fe2+-induced lipid peroxidation. This effect, in combination with its previously found nootropic and neuroprotective properties, made this systemically active dipeptide a promising clinical drug for the treatment of stroke and other disorders associated with deficiency of the endogenous antioxidant system.

Key words

Noopept natural and synthetic antioxidants chemiluminescence human serum lipoproteins 

Abbreviations

CL

chemiluminescence

LPO

lipid peroxidation

PBN

N-tert-butyl-α-phenylnitron

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Giurgea, C., Actualites pharmacologiques, 1972, vol. 25, pp. 115–156.PubMedGoogle Scholar
  2. 2.
    Promyslov, M.S. and Demchuk, M.L., Mol. Chem. Neuropathol., 1995, vol. 25, pp. 69–80.PubMedCrossRefGoogle Scholar
  3. 3.
    Kolpikova, O.C., Farkhutdinov, R.R., Magzhanov, R.V., Korsakov Zh. Nevrologii i Psikhiatrii, 2002, vol. 102, no. 8, pp. 22–25.Google Scholar
  4. 4.
    Gualtieri F., Manetti, D., Romanelli, M.N., et al., Curr. Pharmaceutical Design, 2002, vol. 8, pp. 125–138.CrossRefGoogle Scholar
  5. 5.
    Boldyrev, A.A., Karnozin i zashchita tkanei ot okislitel’nogo stressa (Carnosine and Tissue Defefence from the Oxidative Stress), Moscow: Dialog-Moscow State University, 1999, pp. 37.Google Scholar
  6. 6.
    Gudasheva, T.A., Trofimov, S.S., Ienkina, F.B., et al., Khim.-Farm. Zh., 1985, no. 11, pp. 1319–1322.Google Scholar
  7. 7.
    Gudasheva, T.A., Voronina, T.A., Ostrovskaya, R.U., et al., Eur. J. Med. Chem., 1996, vol. 31, pp. 151–157.CrossRefGoogle Scholar
  8. 8.
    Seredenin, S.B., Voronina, T.A., Ostrovskaya, R.U., et al., US Patent K2 5,439, 930, 1995.Google Scholar
  9. 9.
    Ostrovskaya, R.U., Gudasheva, T.A., Voronina, T.A., et al., Exp. Klin. Farmacol., 2002, vol. 65, no. 5, pp. 66–72.Google Scholar
  10. 10.
    Ostrovskaya, R.U., Gudacheva, T.A., Kravchenko, E.V., et al., Biological Basis of Individual Sensitivity to Psychotropic Drugs, Abstract of Papers, Golden Ring Conference, Seredenin, S.B., Longo, V., Gaviragi, G., Eds., 1994, vol. 1, pp. 79–91.Google Scholar
  11. 11.
    Lysenko, A.V., Uskova, N.I., Ostrovskaya, R.U., et al., Exp. Klin. Farmacol., 1997, vol. 60, no. 3, pp 15–18.Google Scholar
  12. 12.
    Mendzheritskii, A.M., Lysenko, A.V., Demyanenko, S.V., et al., Neurochimiya, 2003, vol. 20, no. 4, pp. 281–286.Google Scholar
  13. 13.
    Ostrovskaya, R., Romanova, G., Barskov, I., et al., Behavioural Pharmacol., 1999, vol. 10, pp. 549–553.CrossRefGoogle Scholar
  14. 14.
    Pelsman, A., Hoyo-Vadillo, Gudasheva, T., et al., Int. J. Devel. Neurosci., 2003, vol. 803, pp. 1–8.Google Scholar
  15. 15.
    Bukanova, Ju., Solnzeva, E., Skrebitsky, V.G., Int. J. Neuropsychopharm., 2002, vol. 5, pp. 229–237.CrossRefGoogle Scholar
  16. 16.
    Andreeva, N.A., Stelmashuk, E.V., Isaev, N.K., et al., Byull. Eksp. Biol., 2000, vol. 130, no. 10, pp. 418–421.Google Scholar
  17. 17.
    Us, K.S., Klodt, P.M., Kudrin, V.S., et al., Int. Symp. “Hyppocampus and memory”, Pushchino, 2006, p. 111.Google Scholar
  18. 18.
    Kovalenko, L.P., Miramedova, M.G., Ostrovskaya, R.U., et al., Eksp. Klin. Farmacol., 2002, vol. 65, no. 2, pp. 53–55.Google Scholar
  19. 19.
    Ostrovskaya, R.U., Lyapina, L.A., Gudasheva, T.A., et al., Eksp. Klin. Farmacol., 2002, vol. 65, no. 2, pp. 34–37.Google Scholar
  20. 20.
    Schulz, J., Henshaw, R., Siwek, D., J. Neurochem., 1995, vol. 64, pp. 2239–2247.PubMedCrossRefGoogle Scholar
  21. 21.
    Zausinger, S., Westermaier, T., Plesnila, N., Stroke, 2003, vol. 34, no. 6, pp. 1526–1532.PubMedCrossRefGoogle Scholar
  22. 22.
    Vladimirov, Yu.A., Archakov, A.I., Perekisnoe okislenie lipidov v biologicheskikh membranakh (Lipid Peroxidation in Biological Membranes), Moscow: Nauka, 1972, pp. 57–58.Google Scholar
  23. 23.
    Vladimirov, Y.A., Proc. Int. Symp. on Natural Antioxidants. Molecular Mechanisms and Health Effects, Parcker, L., Traber, M.G., and Xin, W., Eds., Champaign, Illinois: AOCS Press, 1995, pp. 125–144.Google Scholar
  24. 24.
    Fedorova, T.N., Rebrova, O.Yu., Larskii, E.G., Lab. Delo, 1991, no. 3, pp. 37–39.Google Scholar
  25. 25.
    Fedorova, T.N., Eksp. Klin. Farmacol., 2003, no. 5, pp. 56–58.Google Scholar
  26. 26.
    Ostrovskaya, R.U., Mirzoev, T.Kh., Firova, F.A., et al., Eksp. Klin. Farmacol., 2001, vol. 64, no. 2, pp. 11–14.Google Scholar
  27. 27.
    Tikhadze, A.K., Clinical-Experimental Study of Free Radical Oxidation of Lipids at Atherosclerosis and Antioxidant Correction of Metabolic Disorders of Lipoper-oxides, Extended Abstract of Doctor Sci. (Med.) Dissertation, Moscow: Research Inst., 1999.Google Scholar

Copyright information

© Pleiades Publishing, Ltd. 2007

Authors and Affiliations

  • T. N. Fedorova
    • 1
  • K. S. Us
    • 2
  • R. U. Ostrovskaya
    • 2
  1. 1.Institute of NeurologyRussian Academy of Medical SciencesMoscowRussia
  2. 2.Zakusov Research Institute of PharmacologyRussian Academy of Medical SciencesMoscowRussia

Personalised recommendations